Population pharmacokinetic analysis of rimonabant in healthy subjects.

被引：1
|
作者：
Ferron, GM [1 ]
Grandison, M [1 ]
Lockwood, G [1 ]
机构：
[1] Sanofi Aventis, Malvern, PA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2005年 / 77卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2004.12.058
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P43 / P43
页数：1
相关论文
共 50 条
  • [31] Population pharmacokinetics of cefixime in Chinese male healthy subjects.
    Cui, Y
    Zhou, Y
    Sun, P
    Zhao, X
    Liu, Y
    Sun, Z
    Lu, W
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P24 - P24
  • [32] PHARMACOKINETIC INTERACTION BETWEEN RALOXIFENE AND CHOLECALCIFEROL IN HEALTHY KOREAN MALE SUBJECTS.
    Kang, W.
    Seong, S.
    Ohk, B.
    Kim, H-J.
    Yoon, Y-R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S39 - S39
  • [33] Pharmacokinetic/pharmacodynamic (PK/PD) model for tolvaptan (TOL) in healthy subjects.
    Van Wart, SA
    Cirincione, BB
    Ludwig, EA
    Chen, X
    Shoaf, S
    Grasela, TH
    Mallikaarjun, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P60 - P60
  • [34] ASSESSMENT OF PHARMACOKINETIC INTERACTION BETWEEN PRADIGASTAT AND EFAVIRENZ OR REPAGLINIDE IN HEALTHY SUBJECTS.
    Kulmatycki, K. M.
    Meyers, D.
    Danis, K.
    Neelakantham, S.
    Su, Z.
    Majumdar, T.
    Sam, R.
    Sunkara, G.
    Chen, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S48 - S49
  • [35] LACK OF A PHARMACOKINETIC INTERACTION BETWEEN DIMEBON (LATREPIRDINE) AND DIGOXIN IN HEALTHY SUBJECTS.
    Qiu, R.
    Plowchalk, D.
    Byon, W.
    Terra, S.
    Corrigan, B.
    Mordenti, J.
    Fang, J.
    Fullerton, T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S91 - S91
  • [36] Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy subjects.
    Liu, P
    Foster, G
    Labadie, R
    Gutierrez, MJ
    Sharma, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P40 - P40
  • [37] LACK OF A PHARMACOKINETIC INTERACTION BETWEEN ERTUGLIFLOZIN AND SITAGLIPTIN OR METFORMIN IN HEALTHY SUBJECTS.
    Kumar, V.
    Sahasrabudhe, V.
    Matschke, K.
    Shi, H.
    Alvey, C.
    Fountaine, R. J.
    Hickman, A.
    Saur, D.
    Terra, S. G.
    Zhou, S.
    Krishna, R.
    Cutler, D. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S47 - S47
  • [38] POPULATION PHARMACOKINETIC ANALYSIS OF RILZABRUTINIB IN HEALTHY SUBJECTS AND PATIENTS WITH PEMPHIGUS.
    Ge, S.
    Li, M.
    Lu, Q.
    Katragadda, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S96 - S96
  • [39] POPULATION PHARMACOKINETIC MODEL OF EVOBRUTINIB, A BRUTON'S TYROSINE KINASE INHIBITOR - AN ANALYSIS OF TWO PHASE I CLINICAL TRIALS IN HEALTHY SUBJECTS.
    Papasouliotis, O.
    Mitchell, D.
    Dyroff, M.
    Girard, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S94 - S94
  • [40] Population pharmacokinetic-pharmacodynamic model of nirogacestat effects on B-cell maturation antigen in healthy subjects.
    Shearer, Todd
    Williams, Rex L.
    Johnson, Mark
    Cendrowicz, Ewa
    Leonowens, Cathrine
    Smith, Margaret
    Baughman, Todd
    Breitbach, Caroline J.
    Smith, L. Mary
    Cheng, Shinta
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345